Montis Biosciences
0730.979.429 · rovalta.com · 25/09/2026
ACTIVE
Montis Biosciences
Financial year 2025 · Closed on 31/12/2025
Net result-3,2 M €+31,7 %over 1 year
Gross margin-2,1 M €+42,3 %over 1 year
Equity-5 M €-181,3 %over 1 year
Workforce8,2 ETP-14,6 %over 1 year
Overview
Identity
Source · BCE/KBOMontis Biosciences is a Private limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 8,2 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0730.979.429
- Incorporation
- 24/07/2019
- Legal form
- Private limited company
- Registered office
- Gaston Geenslaan 3
3001 Leuven · FlandreSee on map - Contributed capital
- 15 775 000,00 €
- Latest accounts
- 31/12/2025
- Average workforce
- 8,2 ETP
Activities (NACE)
Joint committees (1)
- 207
Signals
Healthy social debts
Financials
Source · NBB, 6 filingsTrend over 6 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -2,1 M € | +42.3% | -3,6 M € | -15.3% | -3,1 M € | -18.6% | -2,6 M € | -61.4% | -1,6 M € |
| EBITDA | -2,8 M € | +38.1% | -4,5 M € | -7.8% | -4,2 M € | -18.5% | -3,5 M € | -65.8% | -2,1 M € |
| Operating result | -3 M € | +38.2% | -4,8 M € | -6.6% | -4,5 M € | -18.6% | -3,8 M € | -62.1% | -2,3 M € |
| Net result | -3,2 M € | +31.7% | -4,7 M € | -9.8% | -4,3 M € | -17.0% | -3,7 M € | -62.5% | -2,3 M € |
| Balance sheet | |||||||||
| Equity | -5 M € | -181% | -1,8 M € | -160% | 2,9 M € | -59.4% | 7,2 M € | +84.6% | 3,9 M € |
| Total assets | 3 M € | -9.5% | 3,3 M € | -11.9% | 3,7 M € | -55.1% | 8,3 M € | +54.1% | 5,4 M € |
| Cash | 1,5 M € | -20.5% | 1,9 M € | -16.9% | 2,2 M € | -65.9% | 6,6 M € | +81.1% | 3,6 M € |
| Debts | 7,3 M € | +50.2% | 4,9 M € | +538% | 766,3 k € | -9.1% | 843 k € | -0.7% | 848,6 k € |
| Other | |||||||||
| Workforce | 8,2 ETP | -14.6% | 9,6 ETP | -9.4% | 10,6 ETP | +3.9% | 10,2 ETP | +50.0% | 6,8 ETP |
Board of directors
Source · NBB, accounts to 31/12/20257 active · 4 ended
Active mandates
Active
Graeme Martin
ActiveLuc DOCHEZ
ActiveRana Al-Hallaq
ActiveDetlev Biniszkiewicz
ActiveEllie McGUIRE
ActiveGriet Vanpoucke
ActiveEnded mandates
Other companies at this address
Gaston Geenslaan 3 3001 Leuven| Company | CBE no. |
|---|---|
AstriVax Therapeutics● Active | 0787.990.881 |
AUGUSTINE THERAPEUTICS● Active | 0722.705.230 |
COULTREON BIOPHARMA● Active | 1019.429.814 |
K5 Therapeutics● Active | 0757.718.072 |
Metaptys● Active | 0554.664.311 |
Perseus Biomics● Active | 0650.946.412 |
QUOMAK● Active | 0448.488.111 |
ReWind Therapeutics● Active | 0682.626.216 |
| 1040.853.946 | |
Tavira Therapeutics● Active | 0802.591.262 |
VEDRA THERAPEUTICS● Active | 1039.565.628 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 24/07/2019 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 18 months |
| Filing date | 01/07/2026 | 08/07/2025 | 12/07/2024 | 20/07/2023 | 24/10/2022 | 02/07/2021 |
| General meeting | 30/06/2026 | 30/06/2025 | 26/06/2024 | 23/06/2023 | 10/06/2022 | 02/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 6 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 30/06/2026 | 01/07/2026 | Dutch | |
| Abridged model | 31/12/2024 | 30/06/2025 | 08/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 26/06/2024 | 12/07/2024 | Dutch | |
| Abridged model | 31/12/2022 | 23/06/2023 | 20/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 10/06/2022 | 24/10/2022 | Dutch | |
| Abridged model | 31/12/2020 | 02/06/2021 | 02/07/2021 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20257 active · 4 ended
Active mandates
Active
Graeme Martin
ActiveLuc DOCHEZ
ActiveRana Al-Hallaq
ActiveDetlev Biniszkiewicz
ActiveEllie McGUIRE
ActiveGriet Vanpoucke
ActiveEnded mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates09/07/2025DIVERSEN - ONTSLAGEN - BENOEMINGEN
- Other04/09/2024DIVERSEN
- Other02/07/2024DIVERSEN
- Mandates08/08/2023ONTSLAGEN - BENOEMINGEN
- Registered office08/11/2022MAATSCHAPPELIJKE ZETEL
- Mandates10/05/2022ONTSLAGEN - BENOEMINGEN
- Capital / shares01/04/2022STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
- Other23/03/2021STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-3,2 M €↑
- 2024Annual accounts 2024-4,7 M €↓
- 2023Annual accounts 2023-4,3 M €↓
- 2022Annual accounts 2022-3,7 M €↓
- 2021Annual accounts 2021-2,3 M €↑
- 2020Annual accounts 2020-2,6 M €
- 24/07/2019IncorporationPrivate limited company